Beloteca, Inc. Relocates Lab & Corporate Headquarters In San Diego, California
05/12/2017
The new facility currently spans more than 3,500 square feet and will expand to over 6,000 square feet. The larger space allows Beloteca's to increase its in-house product development capabilities and hire more employees in formulation and analytical development.
Beloteca currently has an active development pipeline with more than 15 pharmaceutical products in various stages of development.
According to company officials, the unification of the headquarters and laboratories will provide increased communication and collaboration between development and the other departments resulting in more efficient development of products.
"We are excited to have found this new location as it will enable Beloteca to continue to grow and internalize development over the next several years," said Fred Defesche, CEO of Beloteca, Inc. "The new space is ideal because it allows us to acquire additional space after obtaining approval of our first products without being encumbered by excess expenses while we are in our startup phase,” he added.
Project Announcements
Castelion Plans Sandoval County, New Mexico, Rocket Motor Manufacturing Operations
11/18/2025
Regeneron Pharmaceuticals Plans Saratoga Springs, New York, Manufacturing Operations
11/17/2025
Southwire Expands Heflin, Alabama, Production Operations
11/17/2025
First Solar Plans Gaffney, South Carolina, Operations
11/15/2025
Ashworth Bros. Upgrades Winchester, Virginia, Production Operations
11/15/2025
Feast & Fettle Plans Elkridge, Maryland, Production-Distribution Operations
11/15/2025
Most Read
-
2025’s Top States for Business: How the Winners Are Outpacing the Rest
Q3 2025
-
Rethinking Local Governments Through Consolidation and Choice
Q3 2025
-
The Compliance Reckoning Is Here
Q3 2025
-
Around the Horn: Data Center Supply Chains — What's Next?
Q3 2025
-
First Person: Filter King’s Expansion Playbook
Q3 2025
-
Rethinking Auto Site Strategy in the Age of Tariffs and Powertrain Shifts
Q3 2025
-
Lead with Facts, Land the Deal
Q3 2025